Skip to main content

Table 4 Drug-drug interactions and predicted plasma levels of oral anticoagulants and targeted cancer therapies

From: Management of atrial fibrillation in patients taking targeted cancer therapies

  Oral Anticoagulants
Warfarin Dabigatran Rivaroxaban Apixaban Edoxaban
Tyrosine
Kinase
Inhibitors
Afatinib      
Axitinib      
Bosutinib      
Cabozantinib      
Ceritinib ↑OAC levels   ↑OAC levels ↑OAC levels  
Crizotinib ↑OAC levels ↑OAC levels* ↑OAC levels* ↑OAC levels* ↑OAC levels*
Dasatinib ↑OAC levels & effect ↑OAC effect ↑OAC levels & effect ↑OAC levels & effect ↑OAC effect
Erlotinib ↑OAC levels     
Gefitinib ↑OAC effect     
Ibrutinib ↑OAC effect ↑OAC levels & effect* ↑OAC levels & effect* ↑OAC levels & effect* ↑OAC levels & effect*
Imatinib ↑OAC levels & effect   ↑OAC levels ↑OAC levels  
Lapatinib   ↑OAC levels* ↑OAC levels* ↑OAC levels* ↑OAC levels*
Lenvatinib      
Nilotinib ↑OAC levels ↑OAC levels* ↑OAC levels* ↑OAC levels* ↑OAC levels*
Osimertinib ↑OAC levels   ↑OAC levels ↑OAC levels  
Pazopanib      
Ponatinib      
Regorafenib ↑OAC effect     
Ruxolitinib      
Sorafenib ↑OAC levels & effect    ↑OAC levels  
Sunitinib   ↑OAC levels* ↑OAC levels* ↑OAC levels* ↑OAC levels*
Vandetanib   ↑OAC levels* ↑OAC levels* ↑OAC levels* ↑OAC levels*
  1. Drug-drug interactions are predicted based on pharmacokinetics, given the limited data available from patient studies
  2. Underlined = "Alter combination"
\